German HTA 'a success', says GBA; Industry disagrees
This article was originally published in Scrip
Executive Summary
Industry representatives have claimed that there is still not enough evidence to suggest that Germany's early benefit assessments for new drugs is a success, despite claims to the contrary from the GBA, the body in charge of health technology assessments.